Catalog
Reports
One report per clinical trial. Each shows how many sources were screened and cited, how deep the commentary runs, and when it was last checked. Trials we haven't built a report for yet follow, ready to order.
- 8 reports
- 645 more trials to order
- 8 indications
- 10 drugs
- last updated Oct 8, 2026
- catalog.json
- trials.json
- powered by MedAffairsAI®
/
| Trial | Indication | Phase | Claims | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| PROUD-PV NCT01949805 · AOP Orphan Pharmaceuticals AG | Polycythemia vera | Phase 3 | 749 | 30 | Standard | 2026-10-08 | Preview |
| NEONIPIGA NCT04006262 · GERCOR - Multidisciplinary Oncology Cooperative Group | Gastroesophageal adenocarcinoma | Phase 2 | 1,222 | 60 | Deep | 2026-10-08 | Preview |
| CALGB-10403 NCT00558519 · Alliance for Clinical Trials in Oncology | Leukemia | Phase 2 | 1,065 | 28 | Standard | 2026-10-08 | Preview |
| MARS2 NCT02040272 · Royal Brompton & Harefield NHS Foundation Trust | Mesothelioma | Not applicable | 1,094 | 131 | Deep | 2026-10-08 | Preview |
| EURTAC NCT00446225 · Spanish Lung Cancer Group | Non-small cell lung cancer | Phase 3 | 210 | 9 | Focused | 2026-10-08 | Preview |
| SURTIME NCT01099423 · European Organisation for Research and Treatment of Cancer - EORTC | Renal cell carcinoma | Phase 3 | 427 | 32 | Standard | 2026-10-08 | Preview |
| MSLT-II NCT00297895 · Saint John's Cancer Institute | Melanoma | Not applicable | 499 | 36 | Standard | 2026-10-08 | Preview |
| EA3191 NCT04671667 · National Cancer Institute (NCI) | Head and neck squamous cell carcinoma | Phase 2 | 116 | 9 | Focused | 2026-10-07 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Sources counts what our index has found so far; size is the estimate. Order one; trials with 8 or more sources can also be requested as a free build. | |||||||
| EV-302 NCT04223856 · Astellas Pharma Global Development, Inc. | Urothelial Cancer | Phase 3 | 853 | Deep | not built | View | |
| ADAURA NCT02511106 · AstraZeneca | Stage IB-IIIA Non-small Cell Lung Carcinoma | Phase 3 | 784 | Deep | not built | View | |
| FLAURA2 NCT04035486 · AstraZeneca | Non-Small Cell Lung Cancer | Phase 3 | 758 | Deep | not built | View | |
| monarchE NCT03155997 · Eli Lilly and Company | Breast Cancer | Phase 3 | 631 | Deep | not built | View | |
| SERENA-6 NCT04964934 · AstraZeneca | ER-Positive HER2-Negative Breast Cancer | Phase 3 | 618 | Deep | not built | View | |
| TALAPRO-2 NCT03395197 · Pfizer | mCRPC | Phase 3 | 560 | Deep | not built | View | |
| CARTITUDE-4 NCT04181827 · Janssen Research & Development, LLC | Multiple Myeloma | Phase 3 | 546 | Deep | not built | View | |
| NCT03036488 NCT03036488 · Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | Phase 3 | 514 | Deep | not built | View | |
| NATALEE NCT03701334 · Novartis Pharmaceuticals | Early Breast Cancer | Phase 3 | 502 | Deep | not built | View | |
| CheckMate 816 NCT02998528 · Bristol-Myers Squibb | Non Small Cell Lung Cancer | Phase 3 | 501 | Deep | not built | View | |
| DB-06 NCT04494425 · AstraZeneca | Advanced or Metastatic Breast Cancer | Phase 3 | 457 | Deep | not built | View | |
| MARIPOSA-2 NCT04988295 · Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | Phase 3 | 381 | Deep | not built | View | |
| ESOPEC NCT02509286 · University Hospital Schleswig-Holstein | Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction | Phase 3 | 373 | Deep | not built | View | |
| NCT03142334 NCT03142334 · Merck Sharp & Dohme LLC | Renal Cell Carcinoma | Phase 3 | 368 | Deep | not built | View | |
| MajesTEC-3 NCT05083169 · Janssen Research & Development, LLC | Multiple Myeloma | Phase 3 | 354 | Deep | not built | View | |
| NCT03924895 NCT03924895 · Merck Sharp & Dohme LLC | Urinary Bladder Cancer, Muscle-invasive | Phase 3 | 352 | Deep | not built | View | |
| NCT04784715 NCT04784715 · AstraZeneca | Breast Cancer; HER2-positive; Metastatic | Phase 3 | 347 | Deep | not built | View | |
| NCT03734029 NCT03734029 · Daiichi Sankyo | Breast Cancer | Phase 3 | 344 | Deep | not built | View | |
| CARTITUDE-1 NCT03548207 · Janssen Research & Development, LLC | Multiple Myeloma | Phase 1/Phase 2 | 334 | Deep | not built | View | |
| ASCENT-04 NCT05382286 · Gilead Sciences | Triple Negative Breast Cancer, PD-L1 Positive | Phase 3 | 321 | Deep | not built | View | |
| ARASENS NCT02799602 · Bayer | Metastatic Hormone-sensitive Prostate Cancer | Phase 3 | 305 | Deep | not built | View | |
| KarMMa-3 NCT03651128 · Celgene | Multiple Myeloma | Phase 3 | 300 | Deep | not built | View | |
| IMvigor011 NCT04660344 · Hoffmann-La Roche | Muscle-invasive Bladder Cancer | Phase 3 | 300 | Deep | not built | View | |
| CheckMate 274 NCT02632409 · Bristol-Myers Squibb | Various Advanced Cancer | Phase 3 | 297 | Deep | not built | View | |
| CheckMate901 NCT03036098 · Bristol-Myers Squibb | Urothelial Cancer | Phase 3 | 297 | Deep | not built | View | |
8 of 8 reports · 645 of 645 trials without a report
By indication
Don't see your trial? Type its NCT id in the search above to look it up. New reports are built from the trial's registry record and the public commentary that names it.